Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Post by Steveminon Apr 14, 2021 3:30pm
147 Views
Post# 32994399

Inmed Webinar

Inmed WebinarApril 28th Inmed (Adams and Colwill) will be doing a "webinar" through Edison (remember, Inmed PAYS Edison for their coverage).

They say they are going to give an "overview of the company's recent operating and financial activiites followed by a brief Q&A session".

The timing of this makes no sense. They are due to report qtrly numbers just a couple of weeks after this, why not wait until then to regurgitate the same old BS?? Why a "brief" Q&A session? Well because these questions will all be pre determined -- there's no way either of these two guys will take an off the cuff question because they know precisely how pissed off their shareholders are and won't dare engage with them.
This is just an attempt to placate shareholders and make us feel like they are finally listening to  and answering questions that have gone unanswered for months (and years).

I have no idea what they could possibly says that hasnt been said already - unless they announce they are doing another cap raise!! With Adams, you just never know. And Colwill is so arrogant and patronizing that there's no way you'll get anything useful from him. This webinar will be a huge waste of time.....

HEY ADAMS - How about you focus on stopping this years long epic destruction of shareholder value?? It is time for you to go.


<< Previous
Bullboard Posts
Next >>